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Background: Trastuzumab + chemotherapy is considered the standard therapy for advanced human epidermal
growth factor receptor 2 (HER2)-positive gastric cancer with mild manageable toxicity, on the basis of the results of
a pivotal phase-III trial. Cerebrovascular events are not recognized as expected adverse effects of such therapy.
Case presentation: We report the case of a 67-year-old, current-smoking male with stage-IV HER2-positive gastric
cancer who suffered right middle cerebral artery (MCA) embolism after trastuzumab + chemotherapy. He received
trastuzumab and cisplatin on Day 1, followed by a continuous 5-fluorouracil infusion for 5 days as a first-line treatment.
Four days after chemotherapy initiation, he presented with left hemiplegia, and brain magnetic resonance imaging
and magnetic resonance angiography revealed a right MCA occlusion. No further chemotherapy was administered
because of worsening performance status.
Conclusion: The present case, possibly the first such reported case, suggests the risk of development of
embolism after trastuzumab + chemotherapy in HER2-positive advanced gastric cancer, although other factors
should be considered.
Keywords: Intracranial embolism, Chemotherapy, Gastric cancer, Human epidermal growth factor receptor 2Background
Thromboembolism is a known vascular toxicity associ-
ated with tumor chemotherapy. The combination of
trastuzumab and chemotherapy has shown significant
antitumor activity, with mild manageable toxicity in pa-
tients with human epidermal growth factor receptor 2
(HER2)-positive advanced gastric cancer [1], whereas
cerebral arterial embolism has not been recognized as a
side effect expected with this regimen. We describe an
unusual case of advanced gastric cancer, in which the
patient developed right middle cerebral artery embolism
after chemotherapy combined with trastuzumab.
Case presentation
A 67-year-old man was diagnosed with stage-IV gastric
cancer with multiple liver and lymph node metastases,
but no apparent brain metastases, in April 2013. The pa-
tient had no previous medical history of arrhythmia, is-
chemic heart disease, diabetes mellitus, or stroke, and he* Correspondence: takedamasa2004@yahoo.co.jp
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unless otherwise stated.was not taking any daily medications. An echocardiogram
before chemotherapy demonstrated no cardiac thrombus,
no atrial/ventricular septal defects, no patent foramen
ovale, no valvular vegetations, and a left ventricular ejec-
tion fraction (LVEF) of 67%. Immunohistochemical ana-
lysis showed a HER2-positive score of 3+ for a primary
tumor. Thus, the patient was treated with trastuzumab,
and cisplatin on day 1, with subsequent continuous infu-
sion of 5-fluorouracil (5-FU) for 5 days. Although the pa-
tient did not experience any adverse events at the start of
chemotherapy, 4 days afterward, he noticed a sudden on-
set of left hemiplegia and agitation. Laboratory testing
showed grade-1 anemia (hemoglobin, 12.5 g/dL), in-
creased number of platelets (452,000/μL), healthy levels of
fibrinogen (235 mg/dL; reference range 150–340 mg/dL)
and the prothrombin time–international normalized ratio
(PT-INR) of 1.05 (reference range 0.90–1.10), and a slight
increase in fibrin degradation product (FDP) levels to
10.3 μg/mL; reference range 0–4.0 μg/mL). An electrocar-
diogram showed a healthy sinus rhythm with no ST–T
changes. Noncontrast brain computed tomography (CT)
revealed a “dot sign” in the right middle cerebral artery
(MCA) seen as a dot in the sylvian fissure (Figure 1A),ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Brain images after the onset of cerebral infarction. A: Noncontrast brain computed tomography revealed a “dot” sign in the right
middle cerebral artery (MCA; arrow) seen as a dot in the sylvian fissure. B: Brain magnetic resonance angiography (MRA) showing an occlusion of
the right MCA (arrowhead) on the day of the stroke. C: Brain MRA 3 days after the stroke showing blood flow of the damaged area of the brain.
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infarction. Brain magnetic resonance imaging and mag-
netic resonance angiography revealed an MCA occlusion
(Figure 1B), consistent with a diagnosis of chemotherapy-
induced grade-4 stroke. After consultation with a neurolo-
gist, emergency endovascular therapy with an aspiration
catheter and balloon was performed. Removal of the clot
did restore the blood flow; however, distal emboli still
remained (Figure 1C). The patient concomitantly received
argatroban and aspirin. No further chemotherapy was
administered because of the deterioration in the per-
formance status of the patient. He underwent extensive
neurorehabilitation, which brought a slight improvement
in his neurological status. One month after initiation
of chemotherapy, his carcinoembryonic antigen level
decreased from 15.4 ng/mL to 7.6 ng/mL (reference
range 0.0–5.0); however, he developed jaundice be-
cause of the tumor burden due to liver metastasis. His
condition worsened and he died 2.0 months after
chemotherapy initiation.
Discussion and conclusions
The combination of trastuzumab and chemotherapy is
considered the standard of care for patients with HER2-
positive advanced gastric cancer on the basis of the results
of a pivotal phase-III trial, which showed the efficacy of
trastuzumab combined with cisplatin plus capecitabine or5-FU as a first-line therapy [1]. The toxicity profile is mild,
and no severe thromboembolisms such as cerebral infarc-
tion have been reported to date. In the present case, the
patient presented with MCA embolism on the fourth day
of the first cycle of chemotherapy with 5-FU, cisplatin,
and trastuzumab. The mechanism underlying the cere-
brovascular event caused by a chemotherapy regimen is
likely multifactorial, including tumor microemboli and
thromboembolism. The proposed mechanism of tumor
embolization is invasion of the pulmonary veins, with or
without left atrial invasion [2]. In rare cases, a tumor
may invade the venous circulation and spread to the left
side of the heart through a patent foramen ovale, lead-
ing to systemic tumor embolization. The risk of tumor
embolization in the present case appeared to be low be-
cause a chest CT scan had revealed no evidence of intra-
thoracic metastasis from the gastric cancer, and patent
foramen ovale was not detectable on the echocardiogram.
A possible explanation in the present case is that
thromboembolism may be responsible for this cerebro-
vascular event, and several factors may be at work here.
First, platelet activation, alteration of the clotting
cascade, including hyperfibrinolysis, and disturbances of
the prostacyclin–thromboxane homeostasis, increase the
risk of thrombosis 4- to 6-fold in cancer patients com-
pared with the general population [3]. Clinically signifi-
cant disseminated intravascular coagulation is unlikely
Takahama et al. BMC Research Notes  (2015) 8:100 Page 3 of 3in the presence of healthy levels of fibrinogen and PT-
INR; however, increased FDP levels may indicate the
presence of a clot. Second, smoking likely contributes
to an increased stroke risk via both acute effects on the
risk of thrombus generation in narrowed arteries and
via chronic effects related to an increased burden of
atherosclerosis. Nevertheless, the present case had
no other risk factors of stroke, such as hypertension, dia-
betes mellitus, hypercholesterolemia, and atrial fibrillation
[4]. Third, the literature suggests that cisplatin-based
chemotherapy has been associated with an increased
risk of arterial thromboembolic events [5], although se-
vere thromboembolism, similar to that in the present
case, has not been reported as a side effect associated
with this regimen. Fourth, congestive heart failure is as-
sociated with a relatively high risk of venous thrombo-
embolism. Therefore, we should rule out the possibility
of trastuzumab-related thromboembolism, which is asso-
ciated with trastuzumab-related cardiotoxicity. Troponin I
is a strong predictor of reduction in the LVEF in patients
who received chemotherapy (mainly anthracycline-
containing regimens). A study has demonstrated that
troponin I is mainly detected in blood plasma soon
after the first trastuzumab cycle among troponin-
positive breast cancer patients who received trastuzumab-
containing regimens [6-8]. These results suggest that
trastuzumab-induced cardiotoxicity occurs in the early
phase of chemotherapy. The present case had no signs or
symptoms of congestive heart failure, and we did not per-
form further analysis such as echocardiography after the
onset of cerebral infarction. Nonetheless, the possibility of
trastuzumab-related thromboembolism due to cardiotoxi-
city should be taken into account in the present case.
Trastuzumab in combination with platinum-based
chemotherapy is a treatment option in patients with
HER2-positive advanced gastric or those with cancer
of the gastroesophageal junction. The present case sug-
gests the possible risk of the development of cerebral
embolism after chemotherapy initiation, although other
factors should be considered. Further research is needed
to elucidate the mechanisms underlying the neurovascular
adverse events.
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